Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease (CLARITY) dataset

University of Sydney

Dataset description

This dataset includes up to 787 participants receiving an oral angiotensin receptor blocker (no placebo per standard of care in Australia, and telmisartan in India) recruited from seventeen hospitals in India and Australia. Baseline data includes demographics (age, sex, ethnicity, height, and weight), pregnancy status, smoking status, and co-morbidities. Primary follow-up data was collected daily from days 1 to 28 during treatment period and will include clinical outcome (Clinical Health Score), temperature, respiratory measures (oxygen saturation, use of supplemental oxygen), hypotension (vasopressor requirement), incidence of acute kidney injury, and hyperkalaemia (serum potassium concentration of >6.0 mmol/L).
Click to explore relationships graph


COVID-19 |

Source Study

Trial acronym

Not available

Trial ID



Not available


Not available


Not available

Scientific enquiries

Not available

Brief Summary

The Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY) study is a pragmatic prospective, open-label, randomised controlled trial. CLARITY aims to examine the effectiveness of angiotensin II receptor blockers (ARBs) on improving the outcomes of people who tested positive for COVID-19 disease.

Key Inclusion Criteria

Inclusion Criteria: Potential participants must satisfy all of the following: 1. Laboratory-confirmed* diagnosis of Severe Acute Respiratory Syndrome-Coronavirus-2 infection within 10 days prior to randomisation 2. Age = 18 years 3. a) Systolic Blood Pressure (SBP) = 120 mmHg OR b) SBP = 115 mmHg and currently treated with a non-Renin Angiotensin Aldosterone System inhibitor Blood Pressure (BP) lowering agent that can be ceased 4. Participant and treating clinician are willing and able to perfor ....
Read more

Key Exclusion Criteria

Can healthy volunteers participate?




Sample Size    Not Available

Min. age    18 Years

Max. age    N/A

Sex    All

Condition category    Angiotensin Converting Enzyme 2 (ACE2) , Angiotensin Receptor Blocker (ARB) , Coronavirus Disease 2019 (COVID-19) , Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-Cov-2)

Condition code    COVID-19 , Coronavirus Disease 2019


Intervention code Other interventions - Placebo , Treatment: Drugs - Angiotensin Receptor Blockers


Control group Not available

Comparison not available.


Not Available

The data-sharing statement for this study is currently unavailable.

Source study information is derived from the For more information, please see